B细胞急性淋巴细胞白血病:分子病理学新发现、其预后意义及当前分类综述
本文综述B细胞急性淋巴细胞白血病诊断时的基因组病理学,涵盖传统细胞遗传学可检测的病变及仅通过先进分子技术检测的病变;近期描述的多个复发性基因组驱动因素不仅有助于诊断和预后判断,还可能为特定靶向治疗提供机会。
要点
- B细胞急性淋巴细胞白血病仍是儿童非创伤性死亡的主要原因,多数成人患者死于该病。
- 分子生物学和生物信息学进展使更详细的基因组分析和更好的分子生物学理解成为可能。
- 近期描述的复发性基因组驱动因素有助于诊断和预后判断,并可能为特定靶向治疗提供机会。
核心结论
- 近期描述的复发性基因组驱动因素不仅有助于诊断和预后判断,还可能为特定靶向治疗提供机会。
研究设计与样本
- 本文为综述,总结B细胞急性淋巴细胞白血病诊断时的基因组病理学。
主要发现
- 综述涵盖传统细胞遗传学方法可检测的病变以及仅通过先进分子技术检测的病变。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute lymphoblastic leukaemia (ALL) remains a leading cause of non-traumatic death in children, and the majority of adults diagnosed will succumb to the disease. Recent advances in molecular biology and bioinformatics have enabled more detailed genomic analysis and a better understanding of the molecular biology of ALL. A number of recurrent genomic drivers have recently been described, which not only aid in diagnosis and prognostication, but also may offer opportunities for specific therapeutic targeting. The present review summarises B-ALL genomic pathology at diagnosis, including lesions detectable using traditional cytogenetic methods as well as those detected only through advanced molecular techniques.
引用
- Yeung DTO, Osborn MP, White DL, et al. B-cell acute lymphoblastic leukaemia: recent discoveries in molecular pathology, their prognostic significance, and a review of the current classification. Br J Haematol. 2021. PMID: 34747016. doi:10.1111/bjh.17879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。